Hematologic Malignancies

Videos

Dual CD19/22 Targeting CAR-T Therapy Plus Pembrolizumab Promising for DLBCL

07/02/2020

Wendy Osborne, MBBS (Hons), MRCP, FRCPath, discusses results from the phase 1 Alexander study, which evaluated AUTO3 plus pembrolizumab in relapsed/refractory DLBCL.

Wendy Osborne, MBBS (Hons),...

07/02/2020

Oncology

Videos

Roberto Mina, MD, Discusses Preliminary Results from the UNITO-EMN10 Study

06/26/2020

Roberto Mina, MD, discusses results from the randomized, phase 2 UNITO-EMN10 study evaluating ixazomib combinations and maintenance in transplant-ineligible patients with newly diagnosed MM.

Roberto Mina, MD, discusses...

06/26/2020

Oncology

Videos

Novel Allogeneic CAR-T Products Appear Safe in LBCL and FL

06/21/2020

Sattva Neelapu, MD, discusses early results from the ALPHA study suggesting that ALLO-501 and ALLO-647 are safe and may be effective in LBCL and FL.

Sattva Neelapu, MD, discusses...

06/21/2020

Oncology

$Pembrolizumab Improves PFS in Relapsed/ Refractory Classical Hodgkin Lymphoma$

Videos

Pembrolizumab Improves PFS in Relapsed/ Refractory Classical Hodgkin Lymphoma

06/19/2020

John Kuruvilla, MD, FRCPC, discusses the results from the phase 3 KEYNOTE‑204 trial, which compared pembrolizumab against brentuximab vedotin in relapsed/refractory classical Hodgkin lymphoma.

John Kuruvilla, MD, FRCPC,...

06/19/2020

Oncology

Podcasts

Interim Analysis Suggests Correlation Between Ponatinib Dosing and Efficacy in CML

06/11/2020

Jorge Cortes, MD, discusses results from an interim analysis of the OPTIC trial, evaluating the association between ponatinib exposure, efficacy, and safety with response-based dose reduction in CML.

Jorge Cortes, MD, discusses...

06/11/2020

Oncology

$Faster Corticosteroid Tapering Safe in Relapsed/Refractory MM$

Podcasts

Faster Corticosteroid Tapering Safe in Relapsed/Refractory MM

06/03/2020

Ajai Chari, MD, discusses the phase 1b PAVO study, which evaluated the safety of faster corticosteroid tapering in patients with relapsed/refractory MM receiving subcutaneous daratumumab.

Ajai Chari, MD, discusses the...

06/03/2020

Oncology

Conference Insider

Enasidenib Plus Azacitidine Improves Responses in Newly Diagnosed IDH2-Mutated AML

05/31/2020

Combined therapy with enasidenib and azacitidine resulted in significantly improved response rates and durations in older patients with newly diagnosed IDH2-mutated AML.

Combined therapy with enasidenib...

05/31/2020

Oncology

Podcasts

Triplet Combo Well-Tolerated, Effective for IDH1-Mutated AML

05/31/2020

Courtney DiNardo, MD, MSCE, discusses the promising results from a phase 1b/2 study exploring ivosidenib in combination with venetoclax and azacitidine for IDH1-mutated AML.

Courtney DiNardo, MD, MSCE,...

05/31/2020

Oncology

Conference Insider

Weekly Selinexor Added to Bortezomib and Dexamethasone Improves Outcomes in MM

05/30/2020

Once weekly selinexor, bortezomib, and dexamethasone significantly improved PFS and ORR compared to standard twice weekly bortezomib and dexamethasone for MM.

Once weekly selinexor,...

05/30/2020

Oncology

Conference Insider

Zanubrutinib Safe, Tolerable for Waldenström Macroglobulinemia

05/30/2020

Zanubrutinib appears to be associated with a higher CR and VGPR rate and demonstrates clinically meaningful advantages in safety and tolerability compared to ibrutinib for WM.

Zanubrutinib appears to be...

05/30/2020

Oncology